ClinicalTrials.gg
RecruitingNCT06994806Updated Mar 3, 2026

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

A Phase 1 interventional study of KQB168 and Pembrolizumab in Solid Tumor Malignancies, sponsored by Kumquat Biosciences Inc.. Recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Kumquat Biosciences Inc. · Phase 1, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are:

  • What is the safe dose of KQB168 by itself or in combination with pembrolizumab?
  • Does KQB168 alone or in combination with pembrolizumab decrease the size of the tumor?
  • What happens to KQB168 in the body?

Participants will:

  • Take KQB168 daily, alone or in combination with pembrolizumab
  • Visit the clinic about 8 times in the first 8 weeks, and then once every 3 weeks after that
02

Conditions studied

  • Solid Tumor Malignancies
03

In context

Lead sponsor

Kumquat Biosciences Inc. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of solid tumor .
  • Unresectable or disease that has progressed on immunotherapy.
  • No available treatment with curative intent
  • Adequate organ function
  • per v1.1

Exclusion criteria

Exclusion Criteria:

  • Active primary central nervous system tumors
  • Cardiac abnormalities
  • History of lung diseases
  • Any condition that may impair drug absorption or prevent oral dosing
  • Known history of immune-mediated colitis and uncontrolled diseases
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Monotherapy Dose Escalation

    Drug: KQB168 - Oral KQB168

    Drug: KQB168

  • Experimental
    Combo Therapy Dose Escalation

    Drug: KQB168 - Oral KQB168 Drug: pembrolizumab - Intravenous pembrolizumab

    Drug: KQB168 · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients who experience treatment-emergent adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)

    Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, SAEs, and DLTs, from first dose of study treatment to 30 days after last dose of study treatment.

    Time frame: up to 36 months

Secondary outcomes

  1. Overall response rate (ORR)

    Using RECIST v1.1

    Time frame: up to 36 months

  2. Duration of response (DOR)

    Using RECIST v1.1

    Time frame: up to 36 months

  3. Time to response (TTR)

    Using RECIST v1.1

    Time frame: up to 36 months

  4. Disease control rate (DCR)

    Using RECIST v1.1

    Time frame: up to 36 months

  5. Progression-free survival (PFS)

    Using RECIST v1.1

    Time frame: up to 36 months

  6. Overall survival (OS)

    using RECIST v1.1

    Time frame: up to 36 months

  7. Concentration-time curve (AUC)

    Time frame: up to 36 months

  8. Maximum plasma concentration (Cmax)

    Time frame: up to 36 months

  9. Time to maximum plasma concentration (tmax)

    Time frame: up to 36 months

  10. Pharmacologically Active Dose (PAD)

    Assessment of tumor and systemic immune activation

    Time frame: up to 36 months

07

Study locations

15 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Nov 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
May 29, 2025
StartActual
Jun 24, 2025
Primary completionEst.
Nov 30, 2027
CompletionEst.
May 31, 2028
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06994806
Lead sponsor
Kumquat Biosciences Inc.
Responsible party
Sponsor
First posted
May 29, 2025
Start date
Jun 24, 2025
Primary completion
Nov 30, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Mar 3, 2026

Study contacts

Kumquat Clinical Development
Contact
kumquatstudies@kumquatbio.com
(858) 214-2700

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion